Here's Why You Should Retain Baxter Stock in Your Portfolio for Now

Baxter's Care & Connectivity Solutions sales grew 5% organically to $502 million in Q2 2026 and Advanced Surgery rose 12% to $331 million, supporting portfolio mix improvement after the Kidney Care divestiture. However, adjusted gross margin declined 210bps year over year to 38.6% and operating margin fell 90bps to 14.2%, with roughly $40 million of net tariff impact expected in the second half and Novum IQ remediation still unresolved. Consensus forecasts 2026 revenue of $11.62 billion, up 3.3%, but adjusted EPS of $2.04, down 10.1% year over year; the EPS estimate has increased $0.13 over the past 60 days.

Analysis

BAX is now a restructuring-and-remediation equity rather than a clean medtech growth story. The market can tolerate modest revenue growth if the simplified portfolio converts into sustained gross-margin recovery; it will not reward the current rerating if cost actions merely offset tariffs and volume under-absorption. The key 1-3 month catalyst is evidence that operating-margin stabilization is occurring without one-time benefits, while the 6-18 month upside case requires Infusion Systems to regain customer trust and mix to continue shifting toward higher-value surgical and connected-care products.

Novum IQ creates a competitive opening that is likely more valuable to BD (BDX), ICU Medical (ICUI), and potentially Fresenius Kabi than currently reflected. Hospital pump purchasing is sticky, but remediation periods force clinical evaluations and can turn a temporary shipment pause into multi-year account losses; competitors can use conversion contracts and service bundles to lock in installed-base share. China tender pressure also matters beyond BAX: it reinforces a bifurcation toward scaled, differentiated procedure-oriented medtech platforms such as ISRG and GMED, whose clinical value proposition is less exposed to commodity-style procurement.

Consensus appears to be treating recent estimate revisions as validation of a turnaround, but earnings quality is the issue: tariff-related items and savings initiatives can obscure underlying decremental margins. Contrarian upside exists if a regulatory clearance timeline permits a faster return of Novum placements, but that outcome should be viewed as an event-driven catalyst rather than base-case earnings. A further gross-margin decline, another remediation delay, or a lower full-year operating-margin framework would likely reverse the stock's relative outperformance quickly.

Key Decisions for Investors

• Maintain BAX as watchlist/underweight rather than add after its rerating; require the next earnings release to show sequential gross-margin improvement excluding discrete tariff items and no reduction in infusion guidance. Falsification of the cautious view: documented Novum relaunch timing plus sustained margin expansion would justify covering within 1-2 quarters.
• Initiate a 3-6 month pair: long GMED / short BAX, sized beta-neutral. GMED offers procedure-volume and product-cycle exposure with a cleaner execution profile, while BAX remains exposed to remediation and procurement-driven pricing; target 10-15% relative return, exit if BAX establishes a credible Novum clearance and relaunch timetable.
• Add BDX or ICUI to a competitive-displacement monitor: evidence of pump-placement acceleration, favorable large-IDN contract wins, or commentary on conversions from competitor systems would support a tactical long over the next two quarters. Do not initiate solely on this article; segment order data and valuation are required.
• Prefer ISRG over broad medtech exposure for a 6-18 month allocation where hospital capital spending is resilient: differentiated clinical economics should be less vulnerable to tender pricing than standardized infusion and IV categories. Risk is procedure-volume deceleration or a multiple reset from weaker capital-equipment orders.